Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAT (nucleic acid testing) tests lead US IVD (in vitro diagnostic) growth

This article was originally published in Clinica

Executive Summary

Comfortable - rather than exciting - growth of the US market for in vitro diagnostics is expected in the coming years. A new report from the Freedonia group (Cleveland, Ohio), In Vitro Diagnostics, predicts market expansion averaging some 7% in each of the next three years, revenues reaching $12,690 million in 2005. Growth will be led by demand for nucleic acid testing, as knowledge of the human genome begins to yield diagnostic tools.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072052

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel